Chemical Abstracts Service (CAS), the world’s authority for chemical information, announced today a three-year agreement for SciFinder®, the choice for chemistry research, with Kalexsyn, a Contract Research Organization (CRO) uniquely positioned to address the needs of the pharmaceutical and biotechnology communities. Through this partnership, Kalexsyn provides unlimited searching in SciFinder for every chemist on its staff.
“There’s no other service that offers what SciFinder brings to the lab,” said Dr. Robert Gadwood, president and chief scientific officer at Kalexsyn. “The content is unmatched both in comprehensiveness and in the quality of the chemistry information accessible through SciFinder.”
Kalexsyn joins a host of other CROs that have chosen SciFinder to advance research projects. In addition to top ranking CROs globally, 47 of the top 50 pharmaceutical and biotechnology companies, and 46 of the top 50 chemical organizations around the world, rely on SciFinder to save valuable time and money by learning from previously disclosed research that is collected, organized and made discoverable by CAS.
Leaders at CROs recognize that allowing their researchers to have access to the same product their client organizations rely on gives them an advantage in the marketplace. A multi-year, unlimited agreement allows researchers at Kalexsyn to explore discovery opportunities while maintaining a predictable budget.
“We are proud to work with Kalexsyn to bring SciFinder to its researchers,” commented Chris McCue, vice president of marketing at CAS. “Whether working in medicinal chemistry, custom synthesis or process development, SciFinder supports organizations like Kalexsyn with more substance, reference and reaction information than any other single source.”
